The Redox Paradox: Cancer's Double-Edged Sword for Malignancy and Therapy

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Reactive oxygen species (ROS) are crucial signaling molecules in cancer, promoting tumor growth and metastasis.
• Cancer cells develop a robust antioxidant defense system, involving Nrf2, glutathione (GSH), and thioredoxin (Trx) pathways, to cope with oxidative stress.
• This redox adaptation sustains oncogenic signaling and tumor survival, representing a potential therapeutic vulnerability.

Purpose of the Study:

• To explore the concept of targeting cancer cell redox homeostasis as a therapeutic strategy.
• To review current and emerging therapeutic approaches that exploit cancer cells' dependence on antioxidant systems.
• To highlight the potential of pro-oxidant therapies and redox-modulating agents in cancer treatment.

Main Methods:

• Review of preclinical data and clinical trials on redox-targeted cancer therapies.
• Analysis of mechanisms underlying cancer cell adaptation to oxidative stress.
• Discussion of various therapeutic agents and strategies, including high-dose vitamin C, arsenic trioxide, Nrf2 inhibitors, GSH system inhibitors, thioredoxin system inhibitors, and redox-active metal complexes.

Main Results:

• Cancer cells exhibit a heightened dependence on antioxidant systems for survival.
• Pro-oxidant therapies and inhibitors of key antioxidant pathways demonstrate significant tumor-selective toxicity.
• Novel strategies like redox-active metal complexes show promise in clinical trials by leveraging differential redox states between cancer and normal cells.

Conclusions:

• Targeting the redox balance in cancer cells is a rational and potent therapeutic approach.
• Exploiting cancer's reliance on antioxidant defenses offers a novel frontier for targeted cancer therapy.
• Pharmacological manipulation of redox homeostasis presents a promising avenue for cancer treatment, with ongoing clinical investigations.